{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"14.0","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"The OS time was defined as the time from first administration of trial treatment until death. The OS time was analyzed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat analysis set included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 87 weeks (Data reported are per pre-specified interim analysis with a data cut-off date of 3 Mar 2016)","title":"Part A: Interim Analysis: Overall Survival (OS) Time","type":"SECONDARY","unitOfMeasure":"Months"}